A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT02205528 on ClinicalTrials.gov · last registry update 2020-07-21

Finished 15 September 2015, after enrolling 108 people. Primary outcome, as filed: Change in HbA1c. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 108
Started: 2014-08-18
Primary completion: 2015-09-15 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Diabetes · Diabetes Mellitus Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.